Demyelinating events following anti-tumor necrosis factor alpha therapy: Rare but challenging to treat. Kalen E, Piehl F, Andersson M. Eur J Neurol 2022;29:2047-2055.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kalen E, Piehl F, Andersson M. Demyelinating events following anti-tumor necrosis factor alpha therapy: Rare but challenging to treat. Eur J Neurol 2022;29:2047-2055.
PMID: 35262993